Antihypertensive and antihyperglycemic effects of combinations of losartan with metformin and/or glibenclamide in desoxycorticosterone acetate and streptozotocin-induced hypertensive diabetic rats

Table 3 Effects of losartan, metformin and glibenclamide on weekly fasting blood sugar level of DOCA + STZ hypertensive diabetic rats

Treatment	Post-induction (mg/dL)	Week 1	Week 2	Week 3	Week 4	Week 8
Normal Control	84.40 ± 2.69	76.00 ± 1.26	78.60 ± 0.40	75.20 ± 1.66	75.60 ± 1.57	77.60 ± 3.26
HD Control	354.60 ± 2.09	358.00 ± 12.39^*	357.40 ± 3.36^*	340.20 ± 8.95^*	333.60 ± 8.95^*	301.80 ± 8.45^*
HD + LOS + MET	361.20 ± 7.84	322.20 ± 6.85^*#	291.40 ± 13.76^*#	245.20 ± 6.47^*#	234.80 ± 3.83^*#	205.00 ± 8.44^*#
HD + LOS + GLB	329.60 ± 6.73	294.20 ± 4.92^*#	246.80 ± 8.50^*#a	202.80 ± 3.14^*#a	189.40 ± 8.51^*#a	183.60 ± 9.36^*#
HD + LOS + MET + GLB	382.00 ± 3.51	323.40 ± 10.06^*#	276.80 ± 10.59^*#	213.00 ± 3.00^*#a	160.40 ± 9.04^*#a	150.40 ± 8.21^*#a

All values are expressed as mean ± SEM (n = 5). *P < 0.05 when compared with normal control; ^#P < 0.05 when compared with hypertensive diabetic control; ^aP < 0.05 when compared with LOS + MET treatment. (HD Control Hypertensive Diabetic Control, HD Hypertensive Diabetic Rats, LOS Losartan, MET Metformin, GLB Glibenclamide

ISSN: 2233-7660